Photo of Dr Ravi Gupta

Dr Ravi Gupta

Honorary Consultant -Infectious Diseases: University College London

Wellcome Trust Intermediate Clinical Research Fellow:University College London

University College London (UCL)
Department of Infection
Cruciform Building
90 Gower St
London
UK

E: This email address is being protected from spambots. You need JavaScript enabled to view it.

T: +44(0)7500 792 984

  • Wellcome Trust Senior Fellowship in Clinical Science – 2016-2021
  • Wellcome Trust Intermediate Clinical Fellowship – 2011-2016

2015

Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks C, Goodall RL, Spyer M, Kityo C, Pillay D, Gupta RK,  on behalf of the DART Virology Group. Evidence for reduced drug susceptibility without emergence of major protease mutations following protease inhibitor monotherapy failure in the SARA trial. In press, PLoS One 2015

Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks C, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK, on behalf of the DART Virology Group and DART Trial Team. Gag-Protease sequence evolution following protease inhibitor monotherapy treatment failure in HIV-1 viruses circulating in East Africa. AIDS Research and Human Retroviruses 2015 Aug 10. [Epub ahead of print].

Smith NMG, Mlcochova P, Watters SA, Aasa-Chapman, Rabin N, Moore S, Edwards SG, Garson JA, Grant PR, Ferns RB, Kashuba A, Mayor NP,  Schellekens J, Marsh SGE,  McMichael AJ, Perelson AS, Pillay D, Goonetilleke N, Gupta RK. Proof-of-principle for immune control of global HIV-1 reactivation in vivo. Clinical Infectious Diseases 2015; 61 (1):120-8.

Mlcochova P, ApoloniaL, Kluge SF, Sridharan A, Kirchhoff F, Malim MH, Sauter D, Gupta RK. Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. Virology 2015: 482 ;72-78

Lange CM, Hué S, Violari A, Cotton MF, Gibb D, Babiker A, Abdel G, Otwombe K, Panchia R, Jean-Philippe P, McIntyre JA, Pillay D & Gupta RK. Single genome analysis for detecting multi-class drug resistance in HIV-1 infected children on protease inhibitor-based first line therapy. Journal of Acquired Immune Deficiency Syndromes 2015; 69(2):138-44

Sutherland KA, Ghosn J , Gregson J, Mbisa JL , Chaix ML, Cohen Codar I, Delfraissy JF, Delaugerre C and Gupta RK. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir. Journal of Antimicrobial Chemotherapy 2015;70(1):243-8

2014

Sutherland KA, Mbisa JL, Ghosn J, Chaix ML, Cohen Codar I, Hue S, Delfraissy JF, Delaugerre C, Gupta RK. Phenotypic characterization of virologic failure following lopinavir/ritonavir monotherapy using full-length gag-protease genes. Journal of Antimicrobial Chemotherapy 2014; 69 (12):3340-3348

Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D. High rate of HIV re-suppression after viral failure on first line antiretroviral therapy in the absence of switch to second line. Clinical Infectious Diseases. 2014 Apr;58(7):1023-6

Mlcochova P, Watters S, Towers GJ, Noursadeghi M, Gupta RK. Vpx complementation of 'non-macrophage tropic' R5 viruses reveals robust entry of infectious HIV-1 cores into macrophages. Retrovirology 2014:11:25

Gupta RK, Marks M, Edwards SG, Smith K, Fletcher K, Lee SM, Ramsay A, Copas AJ, Miller RF. A declining CD4 count and diagnosis of HIV-associated Hodgkin lymphoma: do prior clinical symptoms and laboratory abnormalities aid diagnosis? PLoS One. 2014 Feb 4;9(2):e87442.

Mogambo B, Nazziwa J, Bbosa N, Ahluwahlia M, Gupta RK, Kaleebu P, Parry CM. The Arrival of Untreatable Multi-drug Resistant HIV-1 in sub-Saharan Africa, AIDS. 2014 Jun 1;28(9):1373-4.

2013

Hill A, McBride A, Sawyer W, Clumeck N, Gupta RK.  Resistance at Virological Failure Using Boosted Protease Inhibitors versus non Nucleoside Reverse Transcriptase Inhibitors as First Line Antiretroviral Therapy - Implications for Sustained Efficacy of ART in Resource Limited Settings. Journal of Infectious Diseases 2013; 207:S78-84

Watters S, Mlcochova P, Gupta RK. Macrophages - the neglected barrier to eradication. Current Opinions in Infectious Diseases. 2013 Dec;26(6):561-6.

Gupta RK, Van de Vijvers DAMC, Manicklal S, Wainberg M. Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology 2013;10:82.

Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sonnerberg A & Nachega JB.. Oral Antiretrovirals as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance and the Success of HIV Treatment Programs. Journal of Infectious Diseases 2013;207:S101-6.

Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis. 2013 Jun 15;207 Suppl 2:S49-56.

Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK.  The ‘silent’ global burden of congenital CMV. Clinical Microbiology Reviews 2013 Jan;26(1):86-102

2012

Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J, Sawyer W, Hamers RL, Ndembi N, Pillay D, Bertagnolio S. Global trends in antiretroviral resistance in untreated HIV-1 infected individuals following ART roll-out in resource-limited settings: a global collaborative study and meta-regression analysis. The Lancet 2012; 380(9849):1250-8

Clotet B, Hill A, van Delft Y, Gupta RK, Moecklinghoff C. Interpretation of resistance data from randomized trials of first-line antiretroviral treatment. AIDS Rev. 2012 Oct;14(4):247-55 (4.0;1)

2015

Smith, N. M. G., Mlcochova, P., Watters, S. A., Aasa-Chapman, M. M. I., Rabin, N., Moore, S., … Gupta, R. K. (2015). (joint senior author) Proof-of-principle for immune control of global HIV-1 reactivation in vivo. Clinical Infectious Diseases, civ219. http://doi.org/10.1093/cid/civ219

Sutherland KA, Ghosn J , Gregson J, Mbisa JL , Chaix ML, Cohen Codar I, Delfraissy JF, Delaugerre C and Gupta RK. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir. Journal of Antimicrobial Chemotherapy 2015;70(1):243-8

2014

Sutherland KA, Mbisa JL, Ghosn J, Chaix ML, Cohen Codar I, Hue S, Delfraissy JF, Delaugerre C, Gupta RK. Phenotypic characterization of virologic failure following lopinavir/ritonavir monotherapy using full-length gag-protease genes. Journal of Antimicrobial Chemotherapy 2014; 69 (12):3340-3348

Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D. High rate of HIV re-suppression after viral failure on first line antiretroviral therapy in the absence of switch to second line. Clinical Infectious Diseases. 2014 Apr;58(7):1023-6

2013

Hill A, McBride A, Sawyer W, Clumeck N, Gupta RK.  Resistance at Virological Failure Using Boosted Protease Inhibitors versus non Nucleoside Reverse Transcriptase Inhibitors as First Line Antiretroviral Therapy - Implications for Sustained Efficacy of ART in Resource Limited Settings. Journal of Infectious Diseases 2013; 207:S78-84

HIV Virology